➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Medtronic
Merck
Johnson and Johnson
Colorcon

Last Updated: June 25, 2021

DrugPatentWatch Database Preview

EVOMELA Drug Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Evomela, and what generic alternatives are available?

Evomela is a drug marketed by Acrotech and is included in one NDA. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has ninety-six patent family members in twenty countries.

The generic ingredient in EVOMELA is melphalan hydrochloride. There are twelve drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the melphalan hydrochloride profile page.

Drug patent expirations by year for EVOMELA
Drug Prices for EVOMELA

See drug prices for EVOMELA

Recent Clinical Trials for EVOMELA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Washington University School of MedicinePhase 1
Omar AljitawiEarly Phase 1
Spectrum Pharmaceuticals, IncPhase 1/Phase 2

See all EVOMELA clinical trials

Pharmacology for EVOMELA
Drug ClassAlkylating Drug
Mechanism of ActionAlkylating Activity
Paragraph IV (Patent) Challenges for EVOMELA
Tradename Dosage Ingredient NDA Submissiondate
EVOMELA POWDER;INTRAVENOUS melphalan hydrochloride 207155 2017-09-08

US Patents and Regulatory Information for EVOMELA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Acrotech EVOMELA melphalan hydrochloride POWDER;INTRAVENOUS 207155-001 Mar 10, 2016 RX Yes Yes   Get Started Free   Get Started Free Y   Get Started Free
Acrotech EVOMELA melphalan hydrochloride POWDER;INTRAVENOUS 207155-001 Mar 10, 2016 RX Yes Yes   Get Started Free   Get Started Free   Get Started Free
Acrotech EVOMELA melphalan hydrochloride POWDER;INTRAVENOUS 207155-001 Mar 10, 2016 RX Yes Yes   Get Started Free   Get Started Free Y   Get Started Free
Acrotech EVOMELA melphalan hydrochloride POWDER;INTRAVENOUS 207155-001 Mar 10, 2016 RX Yes Yes   Get Started Free   Get Started Free Y   Get Started Free
Acrotech EVOMELA melphalan hydrochloride POWDER;INTRAVENOUS 207155-001 Mar 10, 2016 RX Yes Yes   Get Started Free   Get Started Free Y   Get Started Free
Acrotech EVOMELA melphalan hydrochloride POWDER;INTRAVENOUS 207155-001 Mar 10, 2016 RX Yes Yes   Get Started Free   Get Started Free Y   Get Started Free
Acrotech EVOMELA melphalan hydrochloride POWDER;INTRAVENOUS 207155-001 Mar 10, 2016 RX Yes Yes   Get Started Free   Get Started Free Y   Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Harvard Business School
Dow
Baxter
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.